UK Set To Launch Drug Repurposing Project
Plans Include Extended Protection Periods And New ‘Catalyst Fund’
Licensing new uses of existing medicines has several benefits over off-label use, such as offering assurances that the indication is evidence based and subject to an ongoing safety monitoring program, according to a new report.
You may also be interested in...
Departing BGMA leader Warwick Smith highlights successes in the UK off-patent industry’s response to the COVID-19 pandemic but offers unambiguous criticism of Brexit in the concluding part of an exclusive interview with Generics Bulletin.
Finding new uses for older drugs is the objective of a European repurposing project that will begin in early 2020.
Coronavirus Notebook: WHO’s Plan For Vaccine Manufacturing In Lower-Income Countries, UK Urged To Back IP Waiver
The UK’s independent vaccines committee has finalized its recommendations for the second phase of the COVID-19 vaccination program, and safety issues with several vaccines are still hitting the headlines.